Journal: Frontiers in immunology

Article Title: IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy.

doi: 10.3389/fimmu.2023.1338244

Figure Lengend Snippet: FIGURE 3 Upregulation of IL4I1 infers an unfavorable prognosis for glioma. (A) Representative images (left) and quantification (right) showing IL4I1 staining of normal brain tissues (n = 16) and glioma tissues (n = 37) with the anti-IL4I1 antibody, with scale bars 100 µm (up) and 20 µm (down). (B–D) Kaplan– Meier analysis for OS based on three glioma datasets (CGGA, Rembrandt, and GSE16011). (E–G) ROC curves of OS in CGGA, Rembrandt, and GSE16011 datasets. (H, I) Univariate and multivariate analyses of OS based on CGGA-glioma datasets. ****p < 0.0001.

Article Snippet: Dataset Data type WHO grade II WHO grade III WHO grade IV CGGA RNA-seq 291 334 388 Rembrandt Microarray 98 85 130 GSE16011 Microarray 24 85 159 frontiersin.org (1:2000, 60143-1-Ig, Proteintech), CD163 (1:1,000, ab182422, Abcam), CD86 (1:1,000, ab239075, Abcam), and beta-tubulin (1:2000, DF7967, Affinity) overnight.

Techniques: Staining

Journal: Frontiers in immunology

Article Title: IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy.

doi: 10.3389/fimmu.2023.1338244

Figure Lengend Snippet: FIGURE 4 Heightened IL4I1 expression is correlated with the malignant phenotype of gliomas. (A–D) IL4I1 shows a significant increase in GBM (WHO IV) in TCGA, Rembrandt, GSE16011, and CGGA datasets. Additionally, box plots visualizing the associations between IL4I1 and various clinical characteristics based on the CGGA dataset. Specifically: (E) Age. (F) Status. (G) Histology. (H, I) High expression of IL4I1 in IDH wild-type and 1p/19q non-codel gliomas.

Article Snippet: Dataset Data type WHO grade II WHO grade III WHO grade IV CGGA RNA-seq 291 334 388 Rembrandt Microarray 98 85 130 GSE16011 Microarray 24 85 159 frontiersin.org (1:2000, 60143-1-Ig, Proteintech), CD163 (1:1,000, ab182422, Abcam), CD86 (1:1,000, ab239075, Abcam), and beta-tubulin (1:2000, DF7967, Affinity) overnight.

Techniques: Expressing

Journal: Frontiers in immunology

Article Title: IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy.

doi: 10.3389/fimmu.2023.1338244

Figure Lengend Snippet: FIGURE 6 IL4I1 is expressed in M2-like macrophages in glioma. (A) Summary of IL4I1 expression in 12 distinct single-cell datasets from glioma patients. (B) Association between IL4I1 and macrophages on XCELL, TIMER, and EPIC algorithms. (C) Association between IL4I1 expression and markers of M1 and M2 macrophages in CGGA and TCGA databases. Color depth and digital scale represent the strength of association. (D) Representative colocalization images from IF staining between IL4I1 and CD206 in clinical glioma specimens. DAPI (blue), IL4I1 (red) and CD206 (green). Scale bar: 20 mm. (E) Measurement of protein and mRNA expression levels for markers (CD11B, CD204, CD86, CD206, and CD163) of THP-1, M0, M1, and M2 macrophages using WB and RT-qPCR. (F) Assessment of IL4I1 expression in various macrophage subtypes (M0, M1, and M2) and glioma cells (U87, LN229, and U251). (G) Representative IF pictures of the difference of IL4I1 among M0, M1, and M2 macrophages, U87, and LN229 cells with DAPI (blue) and IL4I1 (red). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

Article Snippet: Dataset Data type WHO grade II WHO grade III WHO grade IV CGGA RNA-seq 291 334 388 Rembrandt Microarray 98 85 130 GSE16011 Microarray 24 85 159 frontiersin.org (1:2000, 60143-1-Ig, Proteintech), CD163 (1:1,000, ab182422, Abcam), CD86 (1:1,000, ab239075, Abcam), and beta-tubulin (1:2000, DF7967, Affinity) overnight.

Techniques: Expressing, Staining, Quantitative RT-PCR